image
ADMA Biologics, Inc. ADMA
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 16.29
-1.39 %
$ 3.89 B
Market Cap
19.16
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Aug, 11, 2025.

The intrinsic value of one ADMA stock under the worst case scenario is HIDDEN Compared to the current market price of 16.3 USD, ADMA Biologics, Inc. is HIDDEN

ADMA Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Aug, 11, 2025.

The intrinsic value of one ADMA stock under the base case scenario is HIDDEN Compared to the current market price of 16.3 USD, ADMA Biologics, Inc. is HIDDEN

ADMA Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Aug, 11, 2025.

The intrinsic value of one ADMA stock under the best case scenario is HIDDEN Compared to the current market price of 16.3 USD, ADMA Biologics, Inc. is HIDDEN

ADMA Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart ADMA

image
1M -14.0%
6M -3%
1Y --%
3Y 587%
5Y 438%
All
$25.0$25.0$24.0$24.0$23.0$23.0$22.0$22.0$21.0$21.0$20.0$20.0$19.0$19.0$18.0$18.0$17.0$17.0$16.0$16.0$15.0$15.0Mar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 JulAug '25Aug '25
FINANCIALS
426 M REVENUE
65.15%
Growth Rates
1Year 65.15%
3Years 74.01%
5Years 70.79%
7Years 51.99%
10Years 53.39%
139 M OPERATING INCOME
542.49%
Growth Rates
1Year 542.49%
3Years 63.63%
5Years 39.88%
7Years 27.69%
10Years 26.72%
198 M NET INCOME
800.00%
Growth Rates
1Year 800.00%
3Years 68.20%
5Years 43.54%
7Years 30.71%
10Years 29.97%
119 M OPERATING CASH FLOW
1248.55%
Growth Rates
1Year 1248.55%
3Years 45.12%
5Years 28.89%
7Years 26.50%
10Years 25.98%
-8.58 M INVESTING CASH FLOW
-72.15%
Growth Rates
1Year -72.15%
3Years 14.06%
5Years -17.60%
7Years -6.59%
10Years -7.81%
-58.3 M FINANCING CASH FLOW
-49.53%
Growth Rates
1Year -49.53%
3Years -14.00%
5Years -11.57%
7Years -10.09%
10Years -21.40%
115 M REVENUE
-2.34%
Growth Rates
1Year 65.15%
3Years 74.01%
5Years 70.79%
7Years 51.99%
10Years 53.39%
34.9 M OPERATING INCOME
-8.98%
Growth Rates
1Year 542.49%
3Years 63.63%
5Years 39.88%
7Years 27.69%
10Years 26.72%
26.9 M NET INCOME
-75.96%
Growth Rates
1Year 800.00%
3Years 68.20%
5Years 43.54%
7Years 30.71%
10Years 29.97%
-19.7 M OPERATING CASH FLOW
-39.18%
Growth Rates
1Year 1248.55%
3Years 45.12%
5Years 28.89%
7Years 26.50%
10Years 25.98%
-4.72 M INVESTING CASH FLOW
-71.64%
Growth Rates
1Year -72.15%
3Years 14.06%
5Years -17.60%
7Years -6.59%
10Years -7.81%
-7.13 M FINANCING CASH FLOW
77.03%
Growth Rates
1Year -49.53%
3Years -14.00%
5Years -11.57%
7Years -10.09%
10Years -21.40%
Balance Sheet ADMA Biologics, Inc.
image
Current Assets 331 M
Cash & Short-Term Investments 103 M
Receivables 50 M
Other Current Assets 178 M
Non-Current Assets 157 M
Long-Term Investments 0
PP&E 63.3 M
Other Non-Current Assets 93.9 M
21.11 %10.23 %36.48 %12.96 %19.22 %Total Assets$488.7m
Current Liabilities 55.5 M
Accounts Payable 20.2 M
Short-Term Debt 1.22 M
Other Current Liabilities 34.1 M
Non-Current Liabilities 84.1 M
Long-Term Debt 80.9 M
Other Non-Current Liabilities 3.22 M
14.48 %24.42 %57.92 %Total Liabilities$139.7m
EFFICIENCY
Earnings Waterfall ADMA Biologics, Inc.
image
Revenue 426 M
Cost Of Revenue 207 M
Gross Profit 220 M
Operating Expenses 80.6 M
Operating Income 139 M
Other Expenses -58.7 M
Net Income 198 M
450m450m400m400m350m350m300m300m250m250m200m200m150m150m100m100m50m50m00426m(207m)220m(81m)139m59m198mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
51.48% GROSS MARGIN
51.48%
Averages
1Year 51.48%
3Years 36.27%
5Years 13.02%
7Years -16.85%
10Years -6.58%
32.59% OPERATING MARGIN
32.59%
Averages
1Year 32.59%
3Years 5.14%
5Years -42.09%
7Years -100.93%
10Years -125.80%
46.35% NET MARGIN
46.35%
Averages
1Year 46.35%
3Years -6.62%
5Years -66.34%
7Years -130.45%
10Years -153.88%
56.64% ROE
56.64%
Averages
1Year 56.64%
3Years -6.77%
5Years -35.88%
7Years -104.24%
10Years -258.92%
40.45% ROA
40.45%
Averages
1Year 40.45%
3Years 2.48%
5Years -13.07%
7Years -26.31%
10Years -38.29%
50.31% ROIC
50.31%
Averages
1Year 50.31%
3Years 13.87%
5Years -5.23%
7Years -21.65%
10Years -38.95%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis ADMA Biologics, Inc.
image
150m150m100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 198 M
Depreciation & Amortization 8.04 M
Capital Expenditures -8.58 M
Stock-Based Compensation 0
Change in Working Capital 0
Others -625 K
Free Cash Flow 110 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets ADMA Biologics, Inc.
image
Wall Street analysts predict an average 1-year price target for ADMA of $10.8 , with forecasts ranging from a low of $4 to a high of $18 .
ADMA Lowest Price Target Wall Street Target
4 USD -75.45%
ADMA Average Price Target Wall Street Target
10.8 USD -34.01%
ADMA Highest Price Target Wall Street Target
18 USD 10.50%
Price
Max Price Target
Min Price Target
Average Price Target
25252020151510105500Sep '24Sep '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26Aug '26Aug '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership ADMA Biologics, Inc.
image
Sold
0-3 MONTHS
10.9 M USD 4
3-6 MONTHS
848 K USD 1
6-9 MONTHS
1.35 M USD 2
9-12 MONTHS
15 M USD 5
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note In the latest trading session, Adma Biologics (ADMA) closed at $18.59, marking a +1.81% move from the previous day. zacks.com - 1 week ago
ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025 RAMSEY, N.J. and BOCA RATON, Fla. globenewswire.com - 1 week ago
Adma Biologics (ADMA) Rises As Market Takes a Dip: Key Facts The latest trading day saw Adma Biologics (ADMA) settling at $18.26, representing a +1.44% change from its previous close. zacks.com - 1 week ago
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter? zacks.com - 2 weeks ago
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider Adma Biologics (ADMA) concluded the recent trading session at $17.13, signifying a +2.39% move from its prior day's close. zacks.com - 3 weeks ago
Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors In the most recent trading session, Adma Biologics (ADMA) closed at $17.98, indicating a -3.75% shift from the previous trading day. zacks.com - 3 weeks ago
Adma Biologics (ADMA) Outperforms Broader Market: What You Need to Know Adma Biologics (ADMA) concluded the recent trading session at $18.34, signifying a +2.98% move from its prior day's close. zacks.com - 1 month ago
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy? Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter? zacks.com - 1 month ago
Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note Adma Biologics (ADMA) closed at $18.16 in the latest trading session, marking a -1.3% move from the prior day. zacks.com - 1 month ago
Will Strong Asceniv Sales Drive ADMA Biologics Further? ADMA rides on record Asceniv sales and FDA-backed yield boost, but valuation concerns and EPS downgrades cloud its outlook. zacks.com - 1 month ago
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today? ADMA's surging Asceniv demand and bold revenue forecasts set it apart in the competitive plasma therapies space. zacks.com - 1 month ago
Here's Why Adma Biologics (ADMA) Fell More Than Broader Market Adma Biologics (ADMA) closed the most recent trading day at $17.74, moving 2.15% from the previous trading session. zacks.com - 1 month ago
8. Profile Summary

ADMA Biologics, Inc. ADMA

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 3.89 B
Dividend Yield 0.00%
Description ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Contact 465 State Route 17, Ramsey, NJ, 07446 https://www.admabiologics.com
IPO Date Oct. 17, 2013
Employees 685
Officers Mr. Adam S. Grossman Co-Founder, President, Chief Executive Officer & Director Mr. Brad Tade Chief Financial Officer & Treasurer Ms. Kaitlin Kestenberg Chief Operating Officer & Senior Vice President of Compliance Mr. Michael Goldstein General Counsel Mr. Drew Pantello Vice President of Marketing & Corporate Development Ms. Cindy Petersen Vice President of Human Resources Dr. Jerrold B. Grossman D.P.S., Ph.D. Co-Founder & Vice Chairman of the Board Mr. John Hafl Executive Director of Sales Mr. Skyler Bloom Senior Director of Business Development & Corporate Strategy